Vitamin D Treatment Attenuates Heart Apoptosis After Coronary Artery Bypass Surgery: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The aim of this study is to examine the effect of vitamin D treatment on the apoptosis and inflammatory changes developed after CABG.

The right atrium sample was taken to assess caspases 2, 3, and 7 activity using immunohistochemistry method.

Why It Was Studied

Vitamin D plays an important role in immune system and in the regulation of inflammatory cytokines.

Who Took Part

The abstract describes 70 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This trial was conducted on 70 patients undergoing CABG with CPB.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The serum level of interleukin-10 (IL-10) and insulin-like growth factor 1 (IGF-1) were compared at intervals.

What Was Measured

The subject headings attached to it are Apoptosis, Biomarkers, Cardiopulmonary Bypass, Caspases, Coronary Artery Bypass, Dietary Supplements and Heart Atria.

The authors tagged it with the keywords coronary artery disease, insulin-like growth factor 1, interleukin-10 and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 70 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Journal of cardiovascular pharmacology and therapeutics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.